Gene | Disease | Score gda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
0.100 | Biomarker | HPO | |||||||||||
|
|
0.100 | Biomarker | HPO | |||||||||||
|
|
0.100 | Biomarker | HPO | |||||||||||
|
|
0.100 | Biomarker | HPO | |||||||||||
|
|
0.100 | Biomarker | HPO | |||||||||||
|
|
0.010 | Biomarker | BEFREE | CD36 inhibits β-catenin/c-myc-mediated glycolysis through ubiquitination of GPC4 to repress colorectal tumorigenesis. | 31484922 | 2019 |
||||||||
|
|
0.100 | Biomarker | HPO | |||||||||||
|
|
0.100 | Biomarker | HPO | |||||||||||
|
|
0.100 | Biomarker | HPO | |||||||||||
|
|
0.100 | Biomarker | HPO | |||||||||||
|
|
0.010 | Biomarker | BEFREE | Reducing glypican-4 in ES cells improves recovery in a rat model of Parkinson's disease by increasing the production of dopaminergic neurons and decreasing teratoma formation. | 24920634 | 2014 |
||||||||
|
|
0.100 | Biomarker | HPO | |||||||||||
|
|
0.100 | Biomarker | HPO | |||||||||||
|
|
0.100 | Biomarker | HPO | |||||||||||
|
|
0.100 | Biomarker | HPO | |||||||||||
|
|
0.100 | Biomarker | HPO | |||||||||||
|
|
0.100 | Biomarker | HPO | |||||||||||
|
|
0.100 | Biomarker | HPO | |||||||||||
|
|
0.010 | Biomarker | BEFREE | Our results reveal a CD36-GPC4-β-catenin-c-myc signaling axis that regulates glycolysis in CRC development and may provide an intervention strategy for CRC prevention. | 31484922 | 2019 |
||||||||
|
|
0.010 | Biomarker | BEFREE | Glypican-4 (GPC4) is one of the members of the glypicans family, which underlies human congenital malformations and multiple diseases. | 30010221 | 2018 |
||||||||
|
|
0.100 | Biomarker | HPO | |||||||||||
|
|
0.100 | Biomarker | HPO | |||||||||||
|
|
0.100 | Biomarker | HPO | |||||||||||
|
|
0.100 | Biomarker | HPO | |||||||||||
|
|
0.100 | Biomarker | HPO |